Medidata
In previous reports, Medidata has presented a metric showing that—as an industry average—significantly less than 3% of all eCRF data is ever updated after it’s initially entered by investigative sites. This reveals the strikingly low impact—or “return on investment”—that all of the data reviews conducted by the study team, including 100 percent source document verification (SDV), have on the quality of the data. Further evidence to this point was recently published in the TransCelerate BioPharma position paper on risk-based monitoring. According to TransCelerate’s analysis, only 2.4% of all eCRF data queries were SDV-driven queries focused on critical data points (i.e., data supporting critical efficacy and/or safety analyses).
Here the analysis has been taken a step further to determine the relative contribution of different query sources on the total eCRF data cleaning effort by assessing the percentage of data corrections driven by four standard query types:
The accompanying graph is based on data from the Medidata Insights™ metrics warehouse, which currently includes operational metrics from over 6,000 studies contributed by more than 100 sponsor organizations.
Close to half (48.8%) of all data corrections are driven by system-generated auto-queries. In other words, virtually half of all electronic case report form (eCRF) data cleaning is accomplished by the site’s interaction with the EDC system prior to any intervention from site monitors, data managers, and any other study team data reviewers. Most of the remaining data cleaning is split between data management and site monitor queries.
Many professionals in clinical research have questioned the value of configuring so many edit checks into the EDC system for each new study, suggesting that it represents a significant effort and that many never “fire” as auto-queries. It is indeed the case that many auto-queries never “fire,” but the above result makes it clear that the overall up-front investment in configuring EDC edit checks is well worth the downstream benefit. While many don’t end up “firing,” edit checks can be thought of as a very low-cost insurance policy supporting optimal data quality.
Medidata will continue to reveal trends and analyses conducted using the Medidata Insights tool and is, as always, very keen to hear from you on this topic. Is this the result you expected?
—Medidata Solutions, www.mdsol.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.